These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2189230)

  • 1. Post-marketing drug surveillance--concepts, insights and applications.
    Fassihi AR; Robertson SS
    S Afr Med J; 1990 Jun; 77(11):577-80. PubMed ID: 2189230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing evaluations help determine contraceptive safety, efficacy.
    Netw Res Triangle Park N C; 1988; 9(2):1-2, 7. PubMed ID: 12280950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The safety of drugs].
    de Cea Lavech de Chancy H
    Rev Clin Esp; 1990 Sep; 187(4):184-90. PubMed ID: 2091076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contraceptive development and clinical trials.
    Fraser IS
    Clin Reprod Fertil; 1986 Feb; 4(1):75-85. PubMed ID: 3708511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacologic surveillance and safety evaluation of new drugs].
    Reys LL
    Acta Med Port; 1991; 4(3):141-6. PubMed ID: 1950664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
    André FE; Foulkes MA
    Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric cardiovascular safety: challenges in drug and device development and clinical application.
    Bates KE; Vetter VL; Li JS; Cummins S; Aguel F; Almond C; Dubin AM; Elia J; Finkle J; Hausner EA; Joseph F; Karkowsky AM; Killeen M; Lemacks J; Mathis L; McMahon AW; Pinnow E; Rodriguez I; Stockbridge NL; Stockwell M; Tassinari M; Krucoff MW
    Am Heart J; 2012 Oct; 164(4):481-92. PubMed ID: 23067905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of almotriptan in postmarketing surveillance studies.
    Pascual J
    Eur Neurol; 2005; 53 Suppl 1():34-40. PubMed ID: 15920336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmarketing surveillance versus clinical trials: which benefits the patient?
    Lawson DH
    Cardiology; 1994; 85 Suppl 1():18-23. PubMed ID: 7743530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Postmarketing herbs clinical evaluation should concern about re-evaluating symptoms].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1498-500. PubMed ID: 20822030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of black box warning by mining patterns of Convergent Focus Shift in clinical trial study populations using linked public data.
    Ma H; Weng C
    J Biomed Inform; 2016 Apr; 60():132-44. PubMed ID: 26851401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults.
    Hilmer SN; Gnjidic D; Abernethy DR
    J Gerontol A Biol Sci Med Sci; 2012 Feb; 67(2):181-8. PubMed ID: 21653991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contribution of data of efficacy trials to judge the improvement of the medical usefulness of a drug].
    Bouvenot G; Eschwège E
    Therapie; 1992; 47(1):17-9. PubMed ID: 1523589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of postmarketing research.
    Venulet J
    Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.